FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

By News Health
10 hours Ago

(MedPage Today) — An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer…

Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/115713

Author :

Publish date : 2025-05-22 13:41:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

FDA Panel Recommends Monovalent COVID Vaccine for Next Season

Study Links GLP-1 Drugs to Lower Cancer Risk

FDA Chief Defends Job Cuts, COVID Booster Policy at Senate Hearing

Prasugrel Strategy Rolls Short DAPT and De-Escalation Into One

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

AI Assistance May Boost Accuracy of HER2-Low Scoring for Breast Cancers